One sachet of granules for vaginal solution contains 500 mg benzidamine hydrochloride and excipients: sodium chloride, trimethylcetylammonium-p-toluensulfonate, povidone.
Pharmacotherapeutic group: anti-inflammatory products for vaginal administration.
Therapeutic indications:
Vulvovaginitis and cervicovaginitis of various etiologies, including those due to chemotherapy or radiotherapy. Pre- and postoperative prophylactic treatment in gynecological surgery and during the puerperal period.
Contraindications: Hypersensitivity to benzidamine hydrochloride or any of the excipients of the product.
Precautions:
Prolonged use of the product can cause local sensitization phenomena. In this case, the treatment will be interrupted and appropriate treatment will be instituted. If after a short period of time the symptoms do not subside, it is necessary to reassess the diagnosis and treatment.
Interactions with other medicinal products, other interactions:
No interactions with other medicinal products were observed.
Special warnings:
Pregnancy and breast-feeding – The product may be used during pregnancy and breast-feeding only after careful evaluation of the maternal therapeutic benefit/potential risk ratio to the fetus.
Effects on ability to drive or use machines – Topical use of benzidamine at recommended doses does not affect the ability to drive or use machines.
Dosage and method of administration:
Dissolve the contents of 1-2 Tantum Rosa sachets in a liter of boiled and cooled water. Unless otherwise recommended, it is used for vaginal irrigation 1-2 times a day. After dissolution, the resulting solution is used immediately. Side effects: No side effects have been observed when using Tantum Rosa.
Overdose: No cases of overdose have been reported.
Storage conditions: Do not use after the expiry date written on the packaging. Store at temperatures below 25°C, in the original packaging. Keep out of reach of children. Double layered paper/polypropylene sachets of 9.45 g granules for vaginal solution.
Reviews
There are no reviews yet.